Liu Liang, Kuang Yuqiong, Wang Zhongcheng, Chen Yun
School of Pharmacy, Nanjing Medical University Nanjing 211166 China
Department of Pharmacy, Zhongnan Hospital of Wuhan University Wuhan 430071 China.
Chem Sci. 2020 Sep 30;11(41):11298-11306. doi: 10.1039/d0sc04481d.
Human epidermal growth factor receptor 2 (HER2) testing has great value for cancer diagnosis, prognosis and treatment selection. However, the clinical utility of HER2 is frequently tempered by the uncertainty regarding the accuracy of the methods currently available to assess HER2. The development of novel methods for accurate HER2 testing is in great demand. Considering the visualization features of imaging and the quantitative capability of mass spectrometry, integration of the two components into a molecular mapping approach has attracted increasing interest. In this work, we reported an integrated chemical mapping approach using a photocleavable peptide-tagged mass probe for HER2 detection. The probe consists of four functional domains, including the recognition unit of an aptamer to catch HER2, a fluorescent dye moiety (FITC) for fluorescence imaging, a reporter peptide for mass spectrometric quantification, and a photocleavable linker for peptide release. After characterization of this novel probe (, conjugation efficiency, binding affinity and specificity, and photolysis release efficiency), the probe binding and photolysis release conditions were optimized. Then, fluorescence images were collected, and the released reporter peptide after photolysis was quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A limit of quantification (LOQ) of 25 pM was obtained, which very well meets the requirements for clinical laboratory testing. Finally, the developed assay was applied for HER2 testing in four breast cancer cell lines and 42 pairs of human breast primary tumors and adjacent normal tissue samples. Overall, this integrated approach based on a photocleavable peptide-tagged mass probe can provide chemical mapping including both quantitative and visual information of HER2 reliably and consistently, and may pave the way for clinical applications in a more accurate manner.
人表皮生长因子受体2(HER2)检测对于癌症的诊断、预后评估及治疗方案选择具有重要价值。然而,目前评估HER2的方法准确性存在不确定性,这常常限制了HER2在临床上的应用。因此,开发准确检测HER2的新方法迫在眉睫。鉴于成像技术的可视化特性和质谱技术的定量能力,将这两种技术整合到分子图谱方法中已引起越来越多的关注。在本研究中,我们报道了一种基于光可裂解肽标记质谱探针的HER2检测集成化学图谱方法。该探针由四个功能域组成,包括用于捕获HER2的适体识别单元、用于荧光成像的荧光染料部分(FITC)、用于质谱定量的报告肽以及用于肽释放的光可裂解连接子。在对这种新型探针进行表征(包括偶联效率、结合亲和力和特异性以及光解释放效率)后,优化了探针的结合和光解释放条件。然后,采集荧光图像,并通过液相色谱-串联质谱(LC-MS/MS)对光解后释放的报告肽进行定量。获得的定量限(LOQ)为25 pM,很好地满足了临床实验室检测的要求。最后,将所开发的检测方法应用于四种乳腺癌细胞系以及42对人乳腺原发性肿瘤和相邻正常组织样本的HER2检测。总体而言,这种基于光可裂解肽标记质谱探针的集成方法能够可靠且一致地提供HER2的定量和可视化化学图谱信息,可能为更准确的临床应用铺平道路。